CCA
CRVS icon

Catalyst Capital Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Catalyst Capital Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-165
Closed -$2K – 457
2016
Q2 		$2K Hold
165
– – ﹤0.01% 379
2016
Q1 		$2K Buy
+165
New +$2.37K ﹤0.01% 459

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Catalyst Capital Advisors's CRVS Position: Q3 2016 in Review

Catalyst Capital Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q3 2016, closing a stake of 165 shares — an estimated $2K sold.

Catalyst Capital Advisors first reported a position in CRVS in Q1 2016 and held it in 2 quarters. The position peaked at $2K in Q2 2016. 45 funds tracked by Wall St. Rank hold CRVS as of Q3 2016.

  • Catalyst Capital Advisors reported no remaining Corvus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 165 Corvus Pharmaceuticals shares in Q3 2016, an estimated $2K.
  • Catalyst Capital Advisors first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's Corvus Pharmaceuticals position peaked at $2K in Q2 2016.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2016.

Based on Catalyst Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.